Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
Junko Murai, Yves Pommier
Annual Review of Cancer Biology (2018) Vol. 3, Iss. 1, pp. 131-150
Closed Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 525
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 359
The expanding universe of PARP1-mediated molecular and therapeutic mechanisms
Dan Huang, W. Lee Kraus
Molecular Cell (2022) Vol. 82, Iss. 12, pp. 2315-2334
Open Access | Times Cited: 159
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L. Lloyd, Paul W.G. Wijnhoven, Antonio Ramos‐Montoya, et al.
Oncogene (2020) Vol. 39, Iss. 25, pp. 4869-4883
Open Access | Times Cited: 152
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Dae-Seok Kim, Cristel V. Camacho, W. Lee Kraus
Experimental & Molecular Medicine (2021) Vol. 53, Iss. 1, pp. 42-51
Open Access | Times Cited: 131
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Alice Bradbury, Sally Hall, Nicola J. Curtin, et al.
Pharmacology & Therapeutics (2019) Vol. 207, pp. 107450-107450
Closed Access | Times Cited: 140
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
Junko Murai, Anish Thomas, Markku Miettinen, et al.
Pharmacology & Therapeutics (2019) Vol. 201, pp. 94-102
Open Access | Times Cited: 135
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
Ahrum Min, Seock Ah Im
Cancers (2020) Vol. 12, Iss. 2, pp. 394-394
Open Access | Times Cited: 109
FAM111A protects replication forks from protein obstacles via its trypsin-like domain
Yusuke Kojima, Yuka Machida, Sowmiya Palani, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 95
Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
Shuai Wang, Lei Han, Jungsoo Han, et al.
Nature Chemical Biology (2019) Vol. 15, Iss. 12, pp. 1223-1231
Open Access | Times Cited: 84
PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
Lotte van Beek, Éilís McClay, Saleha Patel, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5112-5112
Open Access | Times Cited: 68
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Anne Roulston, Michal Zimmermann, Robert Papp, et al.
Molecular Cancer Therapeutics (2021) Vol. 21, Iss. 2, pp. 245-256
Open Access | Times Cited: 65
PARP Inhibitors Resistance: Mechanisms and Perspectives
Elena Giudice, Marica Gentile, Vanda Salutari, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1420-1420
Open Access | Times Cited: 49
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
Linjie Luo, Khandan Keyomarsi
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 607-631
Open Access | Times Cited: 47
PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
Xiaohui Lin, Wenxia Jiang, Johannes Rudolph, et al.
Nucleic Acids Research (2022) Vol. 50, Iss. 7, pp. 3958-3973
Open Access | Times Cited: 41
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Krista Kinneer, Philipp Wortmann, Zachary A. Cooper, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 6, pp. 1086-1101
Open Access | Times Cited: 39
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Kyle Concannon, Benjamin B. Morris, Carl M. Gay, et al.
Molecular Cell (2023) Vol. 83, Iss. 5, pp. 660-680
Open Access | Times Cited: 28
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics
Yi Zeng, Oluwatobi Arisa, Cody J. Peer, et al.
Seminars in Oncology (2023) Vol. 51, Iss. 1-2, pp. 19-24
Closed Access | Times Cited: 26
PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance
Petar-Bogomil Kanev, Aleksandar Atemin, Stoyno Stoynov, et al.
Seminars in Oncology (2023) Vol. 51, Iss. 1-2, pp. 2-18
Open Access | Times Cited: 25
BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality
Xin Li, Lee Zou
Journal of Clinical Investigation (2024) Vol. 134, Iss. 14
Open Access | Times Cited: 13
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 12
A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells
Petar-Bogomil Kanev, Sylvia Varhoshkova, Irina Georgieva, et al.
Cell Reports (2024) Vol. 43, Iss. 5, pp. 114234-114234
Open Access | Times Cited: 10
SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis
Akane Ogawa, Keiichi Izumikawa, Sota Tate, et al.
Molecular Cell (2025)
Open Access | Times Cited: 1
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers
Chao-Guo Cao, Jie Yang, Yong Chen, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 19, pp. 11012-11033
Closed Access | Times Cited: 61
PARP Inhibitors in Cancer Diagnosis and Therapy
Chung Ying Chan, Kel Vin Tan, Bart Cornelissen
Clinical Cancer Research (2020) Vol. 27, Iss. 6, pp. 1585-1594
Open Access | Times Cited: 61
Page 1 - Next Page

Scroll to top